CA
NZ
UK
AU
IND
US
Pharvaris (NASDAQ:PHVS) shares rose in today's session after the company announced that results from its Phase 3 RAPIDe-3 study were published in The Lancet, one of the most widely cited medical journals in the world. The study evaluated deucrictibant, an oral treatment for sudden …
Sagimet Biosciences (NASDAQ:SGMT) shares were little changed in today's session even after the company presented 52-week Phase 3 results for denifanstat, its oral acne treatment, at the Fall Clinical Dermatology Conference 2026. The open-label extension study, conducted in China by license partner Ascletis, tracked …
Teva Pharmaceutical (NYSE:TEVA) shares jumped in today's session after the FDA approved Weltruza, a new once-monthly injectable form of olanzapine for the treatment of schizophrenia in adults. The approval adds a long-acting option to Teva's neuroscience portfolio, which already includes several other branded treatments.
XORTX Therapeutics (NASDAQ:XRTX), aPenny Stocktrading near $1.58, fell sharply in today's session even after the company outlined plans to file a Clinical Trial Application with Health Canada for XRx-026, its lead gout treatment program. The news appears to have disappointed investors who may have …
Humana (NYSE:HUM) gained 14.64% to USD 443.78 in the October 9, 2026 session, giving it aMarket Valuenear USD 53.29 billion, according to published market data. Published reports tie the move to the Medicare Advantage Star Ratings for 2027, which the Centers for Medicare and …
Humana (NYSE:HUM) gained 12.72%, or USD 49.24, to USD 436.36 in the October 9, 2026 session onVolumeof 2.502 million shares. Published reports tie the move to the 2027 Medicare Advantage Star Ratings, which the Centers for Medicare and Medicaid Services released on Thursday, October …
Moderna (NASDAQ:MRNA) rose 5.67% to USD 208.16 in the October 9, 2026 session, a gain of USD 11.16 from a prior close near USD 197.00, on about 13.0 million shares. No company release, filing or analyst action dated October 8 or 9 was found, …
Kardigan (NASDAQ:KARD) gained 9.33% to USD 15.53 in the October 9, 2026 session, a level that works out to about 2.9% below the USD 16 initial public offering price by this article's own arithmetic. No company release, filing or analyst action dated October 8 …
Moderna (NASDAQ:MRNA) rose 5.67% to USD 208.16 in the October 9, 2026 session, a gain of USD 11.16 from a prior close near USD 197.00 (simple arithmetic on two published numbers), on about 13.0 million shares. No company release, filing or analyst action dated …
Novavax (NASDAQ:NVAX) rose about 6.8% to USD 11.78 in the October 9, 2026 session, with market data labelling the move as news and lists aMarket Valuenear USD 1.94 billion. A search of company releases and published reports found no announcement dated October 8 or …
Please wait processing your request...